Form 4: Assembly Biosciences CEO Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
CEO of Assembly Biosciences, Jason A. Okazaki, sold 981 shares of common stock to cover tax withholding obligations related to the vesting and settlement of restricted stock units.
Summary
- On August 2, 2024, Jason A. Okazaki, CEO and President of Assembly Biosciences, Inc., sold 981 shares of the company's common stock.
- The sale was executed to cover tax withholding obligations associated with the vesting and settlement of restricted stock units.
- The shares were sold at a weighted average price of $14.2325, with individual transactions ranging from $14.08 to $14.39.
- Following the transaction, Okazaki directly owns 15,101 shares of Assembly Biosciences common stock.
Sentiment
Score: 6
Explanation: Neutral sentiment. The transaction is a routine sale to cover tax obligations and doesn't necessarily reflect a change in the CEO's confidence in the company.
Industry Context
This is a routine transaction related to executive compensation and tax obligations. It is common for executives to sell shares to cover taxes when restricted stock units vest. It does not necessarily indicate a negative outlook on the company.
Stakeholder Impact
- The sale of shares could have a minor impact on shareholders due to the slight dilution of equity.
Key Dates
| Date | Description |
|---|---|
| 08/02/2024 | Date of the stock sale transaction. |
| 08/05/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.